Drug intelligence / Profile preview

BMND05

Development stage: Preclinical
Lead developer: Biomind Labs
Modality: Small Molecules

Overview

BMND05 is a preclinical drug candidate being developed by Biomind Labs for the treatment of chronic pain. It is a psychedelic-based pharmaceutical product, potentially utilizing 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) as its active ingredient. The drug is characterized as having anti-inflammatory properties and is part of Biomind Labs' broader effort to develop novel delivery systems, including nanotechnology, for psychiatric and neurological conditions. BMND05 is currently in the evaluation or preclinical stage of development, aiming to provide a new therapeutic approach for chronic pain management through the modulation of serotonin receptors and inflammatory pathways.

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on BMND05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMND05.

Explore the full profile